Compare Summit Therapeutics Inc (SMMT) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Yum China Holdings Inc — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while Yum China Holdings Inc trades at $42.92 (market cap $14.11B). The key difference: Summit Therapeutics Inc and Yum China Holdings Inc are close in size by market cap, and Yum China Holdings Inc pays a 2.78% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Yum China Holdings Inc for 77 Days on average.
| SMMT | YUMC | |
|---|---|---|
Market Cap | $13.71B | $14.11B |
Volume | 6,173,057 | 2,350,650 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.38 | $57.95 |
52-Week Low | $12.43 | $39.98 |
Typical Hold Time | 16 Days | 77 Days |
Enterprise Value | $13.04B | $15.02B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
YUMC trades at $41.78, up 2.78% today, but technical indicators signal a bearish trend with strong sell signals from moving averages. Fundamentally, the company shows steady revenue growth, reaching $11.80B in 2025, with consistent earnings beats in recent quarters. Recent developments include the acquisition of Pizza Hut brand ownership in mainland China and expansion of Pizza Hut Burger Bars to 300 locations.
The outlook is mixed: strong analyst consensus (73.68% buy ratings) and a projected 25.63% upside suggest value, but bearish technicals and competitive pressures pose risks. Investors should weigh solid fundamentals against near-term price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
